Please Wait.....
Report
Takeda Pharmaceutical Company Limited (4502:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360? Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI?s, and Recent Trends
Company Report I 2025-02-27 I 142 Pages I Quaintel Research
Report Summary
Takeda Pharmaceutical Company Limited (4502:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends Report is a comprehensive and easily accessible overview of Takeda Pharmaceutical Company Limited's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Takeda Pharmaceutical Company Limited, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Takeda Pharmaceutical Company Limited's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Takeda Pharmaceutical Company Limited's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers Takeda Pharmaceutical Company Limited's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Takeda Pharmaceutical Company Limited's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by Takeda Pharmaceutical Company Limited, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Takeda Pharmaceutical Company Limited operates as a global biopharmaceutical company that engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. Takeda operates in the pharmaceutical industry through two main business segments - prescription drugs and consumer healthcare products. The prescription drugs segment covers gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience.
The consumer healthcare segment includes over-the-counter medicines. Takeda offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. Some of its key products include Entyvio for ulcerative colitis and Crohn's disease, Gattex for short bowel syndrome, Takecab for gastroesophageal reflux disease, Alofisel for complex perianal fistulas, and Dexilant for acid reflux disease. It also offers factor replacement therapies, monoclonal antibodies, targeted cancer therapies, and treatments for central nervous system disorders. Founded in 1781, the company is headquartered in Tokyo, Japan.
Takeda Pharmaceutical Company Limited in the News:-
- 24-Feb-2025 - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
- 24-Feb-2025 - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
- 16-Jan-2025 - Takeda Named Global Top Employer for Eighth Consecutive Year
- 27-Dec-2024 - Takeda Announces Approval of HYQVIA 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
- 13-Dec-2024 - Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
Scope
Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
Comprehensive Understanding of the Takeda Pharmaceutical Company Limited's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Takeda Pharmaceutical Company Limited:
Takeda Pharmaceutical Company Limited Porter's Five Forces Analysis
Takeda Pharmaceutical Company Limited VRIO Analysis
Takeda Pharmaceutical Company Limited BCG Analysis
Takeda Pharmaceutical Company Limited Segmentation, Targeting and Positioning (STP) Analysis
Takeda Pharmaceutical Company Limited Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 7
Charts 8
Takeda Pharmaceutical Company Limited - Key Company Facts 9
Takeda Pharmaceutical Company Limited - Company Description 10
Takeda Pharmaceutical Company Limited - Top Executives 11
Takeda Pharmaceutical Company Limited- Head Office & Locations 13
Head Office - Country 13
Takeda Pharmaceutical Company Limited - Products and Services 14
Products 14
Services 16
Takeda Pharmaceutical Company Limited - Company's Mission and Vision 18
Mission 18
Vision 18
Takeda Pharmaceutical Company Limited - Corporate Strategy 19
Takeda Pharmaceutical Company Limited - Business Description 27
Oncology 28
Rare Diseases 28
PDT immunology 29
Gastroenterology (GI) 29
Others 30
Takeda Pharmaceutical Company Limited - ESG Spotlight 31
Environment 31
Social 32
Corporate Governance 33
Takeda Pharmaceutical Company Limited - SWOT Analysis 34
Overview 34
Strengths 36
Weaknesses 39
Opportunities 41
Threats 43
Takeda Pharmaceutical Company Limited - PESTLE Analysis 45
Overview 45
Political Factors 47
Economic Factors 50
Social Factors 52
Technological Factors 54
Legal Factors 55
Environmental Factors 57
Takeda Pharmaceutical Company Limited - Financial Deep Dive 60
Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price) 60
Profit and Loss Statement 62
Summary of Profit and Loss Statement 62
Balance Sheet 64
Summary of Balance Sheet 64
Cash Flow Statement 66
Summary of Cash Flow Statement 66
Key Financial Ratio Analysis 68
Takeda Pharmaceutical Company Limited - Ratio Charts 69
Activity Ratio Charts 69
Growth Ratios Charts 70
Leverage Ratio Charts 71
Liquidity Ratio Charts 72
Profitability Ratio Charts 73
Competing Players 74
Snapshot of Competing Players 75
AbbVie Inc 75
Key Company Facts 75
Company Description 75
Novartis AG 76
Key Company Facts 76
Company Description 76
Pfizer Inc. 77
Key Company Facts 77
Company Description 77
Merck & Co., Inc. 78
Key Company Facts 78
Company Description 78
F. Hoffmann-La Roche Ltd 79
Key Company Facts 79
Company Description 79
Takeda Pharmaceutical Company Limited - In the News 80
24-Feb-2025 - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) 80
24-Feb-2025 - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) 81
16-Jan-2025 - Takeda Named Global Top Employer for Eighth Consecutive Year 81
27-Dec-2024 - Takeda Announces Approval of HYQVIA 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia 83
13-Dec-2024 - Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas 85
24-Sep-2024 - Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer 87
18-Sep-2024 - Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships To Further Drive Health Impact in 93 Countries 87
07-Aug-2024 - Takeda Receives European Commission Approval for ADZYNMA (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) 91
09-May-2024 - Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement 93
26-Apr-2024 - Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer 93
18-Apr-2024 - U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease 95
15-Apr-2024 - Notice Regarding Issuance of JPY Hybrid Bonds 96
26-Mar-2024 - Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting 97
26-Mar-2024 - Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) 97
19-Mar-2024 - Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL 99
12-Feb-2024 - FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) 101
29-Jan-2024 - Takeda's GAMMAGARD LIQUID Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 105
16-Jan-2024 - U.S. FDA Approves Takeda's HYQVIA as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 108
21-Dec-2023 - Takeda Announces China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies 111
Takeda Pharmaceutical Company Limited - Key Deals 112
30-Jan-2025 - Takeda Announces Acquisition of Own Shares 112
30-Jan-2025 - Takeda Announces Acquisition of Own Shares 113
03-Dec-2024 - Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics 113
14-Jun-2024 - Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) 115
13-May-2024 - AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease 117
26-Feb-2024 - Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas 119
31-Jan-2024 - Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset 120
13-Sep-2023 - Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries 122
23-Mar-2023 - Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan 125
08-Feb-2023 - Takeda Completes Acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary 127
23-Jan-2023 - Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED's Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor 127
13-Dec-2022 - Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics 130
20-Oct-2022 - Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy 132
19-Sep-2022 - Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States 134
Appendix 136
Definitions 136
SWOT Analysis 136
PESTLE Analysis 136
Value Chain Analysis 136
ESG Spotlight 136
Financial Deep Dive 136
Financial Ratios - 137
Activity Ratios 137
Growth Ratios 138
Leverage Ratios 139
Liquidity Ratios 140
Market Ratios 141
Profitability Ratios 141
Research Methodology 142
Disclaimer 143
Contact Us 143
Tables
Table 1: Takeda Pharmaceutical Company Limited - Company Facts
Table 2: Takeda Pharmaceutical Company Limited - Digital Presence
Table 3: Takeda Pharmaceutical Company Limited - Top Executives
Table 4: Takeda Pharmaceutical Company Limited - Products
Table 5: Takeda Pharmaceutical Company Limited - Services
Table 6: Takeda Pharmaceutical Company Limited - Share Price Trend - Feb-2024 to Feb-2025
Table 7: Takeda Pharmaceutical Company Limited - Ratio Analysis - 2021-2024
Table 8: Takeda Pharmaceutical Company Limited - Competing Players
Table 9: Competing Players - AbbVie Inc - Key Company Facts
Table 10: Competing Players - Novartis AG - Key Company Facts
Table 11: Competing Players - Pfizer Inc. - Key Company Facts
Table 12: Competing Players - Merck & Co., Inc. - Key Company Facts
Table 13: Competing Players - F. Hoffmann-La Roche Ltd - Key Company Facts
Charts
Figure 1: Takeda Pharmaceutical Company Limited- SWOT Analysis
Figure 2: Takeda Pharmaceutical Company Limited - PESTLE Analysis
Figure 3: Takeda Pharmaceutical Company Limited - Average Share Price Trend - Feb-2024 to Feb-2025
Figure 4: Takeda Pharmaceutical Company Limited - Profit and Loss Statement - 2021-2024
Figure 5: Takeda Pharmaceutical Company Limited - Balance Sheet - 2021-2024
Figure 6: Takeda Pharmaceutical Company Limited - Cash Flow Statement 2021-2024
Figure 7: Takeda Pharmaceutical Company Limited - Activity Ratio Charts
Figure 8: Takeda Pharmaceutical Company Limited - Growth Ratio Charts (Value %)
Figure 9: Takeda Pharmaceutical Company Limited - Leverage Ratio Charts
Figure 10: Takeda Pharmaceutical Company Limited - Liquidity Ratio Charts
Figure 11: Takeda Pharmaceutical Company Limited - Profitability Ratio Charts (Value %)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security